{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(3)"],"submitter":["Matsuoka N"],"pubmed_abstract":["<h4>Objective</h4>We aimed to compare the incidence of severe infections between mycophenolate mofetil (MMF) and other immunosuppressants in patients with systemic lupus erythematosus (SLE) on maintenance therapy using data from the Lupus Registry of Nationwide Institutions in Japan.<h4>Methods</h4>This study employed a prospective cohort design, including patients with SLE undergoing maintenance therapy. Exposure was defined as MMF treatment, and the control group included individuals who received other immunosuppressants (non-MMF) treatments. Severe infections requiring hospitalisation were the primary outcomes, whereas secondary outcomes included all-cause hospitalisation, changes in prednisolone dosage, disease activity and organ damage. Statistical analyses employed marginal structura"],"journal":["RMD open"],"pagination":["e005558"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12306299"],"repository":["biostudies-literature"],"pubmed_title":["Safety of mycophenolate mofetil in systemic lupus erythematosus maintenance therapy: insights from the LUNA registry in a nationwide prospective cohort study."],"pmcid":["PMC12306299"],"pubmed_authors":["Yoshimi R","Onishi T","Yajima N","Saito K","Miyawaki Y","Inoue E","Ohno S","Temmoku J","Kajiyama H","Kida T","Shimojima Y","Migita K","Nishimura K","Yoshida S","Ichinose K","Matsuo Y","Sato S","Matsumoto H","Sada KE","Fujiwara M","Asano T","Sumichika Y","Ogawa S","Fukita J","Matsuoka N","Fujita Y"],"additional_accession":[]},"is_claimable":false,"name":"Safety of mycophenolate mofetil in systemic lupus erythematosus maintenance therapy: insights from the LUNA registry in a nationwide prospective cohort study.","description":"<h4>Objective</h4>We aimed to compare the incidence of severe infections between mycophenolate mofetil (MMF) and other immunosuppressants in patients with systemic lupus erythematosus (SLE) on maintenance therapy using data from the Lupus Registry of Nationwide Institutions in Japan.<h4>Methods</h4>This study employed a prospective cohort design, including patients with SLE undergoing maintenance therapy. Exposure was defined as MMF treatment, and the control group included individuals who received other immunosuppressants (non-MMF) treatments. Severe infections requiring hospitalisation were the primary outcomes, whereas secondary outcomes included all-cause hospitalisation, changes in prednisolone dosage, disease activity and organ damage. Statistical analyses employed marginal structura","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-31T11:13:19.716Z","creation":"2025-08-28T03:09:49.935Z"},"accession":"S-EPMC12306299","cross_references":{"pubmed":["40701623"],"doi":["10.1136/rmdopen-2025-005558"]}}